PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection
Findings from major health centers to be presented at ASM Microbe 2019 GAITHERSBURG, Md. , June 13, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today that data from its Acuitas ® AMR Gene Panel and Acuitas Lighthouse ®  Software will be presented at ASM Microbe 2019 being held
View HTML
Toggle Summary OpGen Reports First Quarter 2019 Financial Results and Provides Business Update
Submission of 510(k) application to the FDA for clearance of the Acuitas ® AMR Gene Panel test for bacterial isolates  Revenue up 21% Quarter-over-Quarter  Conference call to be held at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc.
View HTML
Toggle Summary OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance
New molecular test designed to detect 47 antibiotic-resistance genes with high sensitivity and specificity in less than three hours, empowering healthcare facilities to make more informed infection control decisions GAITHERSBURG, Md. , May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc.
View HTML
Toggle Summary OpGen Announces Date of First Quarter 2019 Financial Results Conference Call
GAITHERSBURG, Md. , May 07, 2019 (GLOBE NEWSWIRE) -- OpGen , Inc. (NASDAQ: OPGN) announced today that the Company will report its first quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, May 14, 2019. OpGen’s management team will host a live conference call and
View HTML
Toggle Summary OpGen Announces Closing of Public Offering of Common Stock
GAITHERSBURG, Md. , March 29, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today the closing of its previously announced underwritten public offering of 9 million shares of its common stock at a public offering price of $0.60 per share. All of the shares were sold by OpGen .
View HTML
Toggle Summary OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal
Pivotal data supports use of Acuitas Lighthouse® Software for prediction of antibiotic resistance GAITHERSBURG, Md. , March 28, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data supporting prediction of antibiotic resistance using the company’s Acuitas® AMR Gene Panel
View HTML
Toggle Summary OpGen Announces Pricing of a $5.4 Million Public Offering of Common Stock
GAITHERSBURG, Md. , March 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today the pricing of an underwritten public offering of 9 million shares of its common stock at a public offering price of $0.60 per share. The company also granted the underwriters a 45-day option to
View HTML
Toggle Summary OpGen and Merck’s ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
GAITHERSBURG, Md. , March 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, at the VIII International Symposium on Hospital Acquired
View HTML
Toggle Summary OpGen Reports Fourth Quarter and 2018 Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and 12 months ended December 31, 2018 and provided a business update.
View HTML
Toggle Summary OpGen Appoints R. Don Elsey to Board of Directors
GAITHERSBURG, Md. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announces the appointment R. Don Elsey to the company’s board of directors and audit committee, effective February 21 , 2019.  He will serve as chairman of the board’s audit committee and will stand for reelection for
View HTML